NSCLC non-metastatic

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 31/01/2023)

PACIFIC-4 (AstraZeneca) (Stage IA3 or IB or IIA; EGFR-WT)
International Study of Durvalumab/Placebo Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515). 

PACIFIC-4 (AstraZeneca) (Stage I or II; EGFR mutation)
International Study of Osimertinib Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515). 

PACIFIC-8 (AstraZeneca) (Stage III; unresectable)
Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy.